Recreating the tumor microenvironment in a bilayer, hyaluronic acid hydrogel construct for the growth of prostate cancer spheroids

Biomaterials

Volumn 33, Issue 35, 2012, Pages 9049-9060

  Xu, Xian ^a   Gurski, Lisa A ^a   Zhang, Chu ^a,c   Harrington, Daniel A ^b   Farach Carson, Mary C ^a,b   Jia, Xinqiao ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b RICE UNIVERSITY   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

3D tumor model; Growth factor; Hyaluronic acid; Hydrogels; Prostate cancer; Tumoroid

Indexed keywords

GROWTH FACTOR; HYALURONIC ACIDS; PROSTATE CANCERS; TUMOR MODELS; TUMOROID;

CELLS; CROSSLINKING; CYTOLOGY; DIAGNOSIS; DISEASES; ENZYME INHIBITION; MONOLAYERS; ORGANIC ACIDS; PHYSIOLOGY; PROTEINS; THREE DIMENSIONAL; THREE DIMENSIONAL COMPUTER GRAPHICS; TUMORS;

HYDROGELS;

ACRYLIC ACID; CANCER GROWTH FACTOR; CYTOKINE; F ACTIN; HEPARIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HYALURONIC ACID; INTERLEUKIN 8; MESSENGER RNA; THIOL DERIVATIVE; UVOMORULIN; VASCULOTROPIN 165;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ENGINEERING; CELL STRAIN LNCAP; CONTROLLED STUDY; CROSS LINKING; DRUG TARGETING; HUMAN; HUMAN CELL; HYDROGEL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIMULATION; SOLUTION AND SOLUBILITY; STATISTICAL SIGNIFICANCE; STROMA; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; VISCOELASTICITY; YOUNG MODULUS;

ACTINS; BLOTTING, WESTERN; CADHERINS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HEPARIN; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; HYDROGELS; INTERLEUKIN-8; MALE; PROSTATIC NEOPLASMS; RNA, MESSENGER; SPHEROIDS, CELLULAR; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867142208     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.08.061     Document Type: Article

References (71)

1. Hutmacher D.W. Biomaterials offer cancer research the third dimension. Nat Mater 2010, 9:90-93.
2. Verbridge S.S., Chandler E.M., Fischbach C. Tissue-engineered three-dimensional tumor models to study tumor angiogenesis. Tissue Eng Part A 2010, 16:2147-2152.
3. Szot C.S., Buchanan C.F., Freeman J.W., Rylander M.N. 3D in vitro bioengineered tumors based on collagen I hydrogels. Biomaterials 2011, 32:7905-7912.
4. Ghajar C.M., Bissell M.J. Tumor engineering: the other face of tissue engineering. Tissue Eng Part A 2010, 16:2153-2156.
5. Hutmacher D.W., Loessner D., Rizzi S., Kaplan D.L., Mooney D.J., Clements J.A. Can tissue engineering concepts advance tumor biology research?. Trends Biotechnol 2010, 28:125-133.
6. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., et al. Engineering tumors with 3D scaffolds. Nat Methods 2007, 4:855-860.
7. Chen L., Xiao Z., Meng Y., Zhao Y., Han J., Su G., et al. The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials 2012, 33:1437-1444.
8. Ananthanarayanan B., Kim Y., Kumar S. Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform. Biomaterials 2011, 32:7913-7923.
9. Harma V., Virtanen J., Makela R., Happonen A., Mpindi J.-P., Knuuttila M., et al. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS ONE 2010, 5.
10. Ingber D.E. Can cancer be reversed by engineering the tumor microenvironment?. Semin Cancer Biol 2008, 18:356-364.
11. Partanen J.I., Nieminen A.I., Makela T.P., Klefstrom J. Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization. Proc Natl Acad Sci U S A 2007, 104:14694-14699.
12. Cross V.L., Zheng Y., Choi N.W., Verbridge S.S., Sutermaster B.A., Bonassar L.J., et al. Dense type I collagen matrices that support cellular remodeling and microfabrication for studies of tumor angiogenesis and vasculogenesis in vitro. Biomaterials 2010, 31:8596-8607.
13. Loessner D., Stok K.S., Lutolf M.P., Hutmacher D.W., Clements J.A., Rizzi S.C. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31:8494-8506.
14. Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007, 1:84-96.
15. Sieh S., Lubik A.A., Clements J.A., Nelson C.C., Hutmacher D.W. Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model. Organogenesis 2010, 6:181-188.
16. Sell S.A., Wolfe P.S., Garg K., McCool J.M., Rodriguez I.A., Bowlin G.L. The use of natural polymers in tissue engineering: a focus on electrospun extracellular matrix analogues. Polymers 2010, 2:522-553.
17. Gurski L.A., Jha A.K., Zhang C., Jia X.Q., Farach-Carson M.C. Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials 2009, 30:6076-6085.
18. Jia X.Q., Yeo Y., Clifton R.J., Jiao T., Kohane D.S., Kobler J.B., et al. Hyaluronic acid-based microgels and microgel networks for vocal fold regeneration. Biomacromolecules 2006, 7:3336-3344.
19. Lokeshwar V.B., Cerwinka W.H., Isoyama T., Lokeshwar B.L. HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res 2005, 65:7782-7789.
20. Lokeshwar V.B., Rubinowicz D., Schroeder G.L., Forgacs E., Minna J.D., Block N.L., et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 2001, 276:11922-11932.
21. Liu D.C., Pearlman E., Diaconu E., Guo K., Mori H., Haqqi T., et al. Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci USA 1996, 93:7832-7837.
22. Hobarth K., Maier U., Marberger M. Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. Eur Urol 1992, 21:206-210.
23. Lees V.C., Fan T.P.D., West D.C. Angiogenesis in a delayed revascularization model is accelerated by angiogenic oligosaccharides of hyaluronan. Lab Invest 1995, 73:259-266.
24. Bhowmick N.A., Moses H.L. Tumor-stroma interactions. Curr Opin Genet Dev 2005, 15:97-101.
25. Verona E.V., Elkahloun A.G., Yang J., Bandyopadhyay A., Yeh I.T., Sun L.-Z. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Res 2007, 67:5737-5746.
26. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252.
27. Murata T., Mizushima H., Chinen I., Moribe H., Yagi S., Hoffman R.M., et al. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. Cancer Res 2011, 71:6633-6642.
28. Freeman M.R., Paul S., Kaefer M., Ishikawa M., Adam R.M., Renshaw A.A., et al. Heparin-binding EGF-Like growth factor in the human prostate: synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. J Cell Biochem 1998, 68:328-338.
29. Iwamoto R., Mekada E. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev 2000, 11:335-344.
30. Ongusaha P.P., Kwak J.C., Zwible A.J., Macip S., Higashiyama S., Taniguchi N., et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 2004, 64:5283-5290.
31. Xu X., Jha A.K., Duncan R.L., Jia X.Q. Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2. Acta Biomater 2011, 7:3050-3059.
32. Lei Y.G., Gojgini S., Lam J., Segura T. The spreading, migration and proliferation of mouse mesenchymal stem cells cultured inside hyaluronic acid hydrogels. Biomaterials 2011, 32:39-47.
33. Shu X.Z., Liu Y.C., Luo Y., Roberts M.C., Prestwich G.D. Disulfide cross-linked hyaluronan hydrogels. Biomacromolecules 2002, 3:1304-1311.
34. Bitter T., Muir H.M. A modified uronic acid carbazole reaction. Anal Biochem 1962, 4:330-334.
35. Jha A.K., Yang W.D., Kirn-Safran C.B., Farach-Carson M.C., Jia X.Q. Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials 2009, 30:6964-6975.
36. Muir C., Chung L.W.K., Carson D.D., Farach-Carson M.C. Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells. Clin Exp Metastasis 2006, 23:75-86.
37. Jeong K.J., Panitch A. Interplay between covalent and physical interactions within environment sensitive hydrogels. Biomacromolecules 2009, 10:1090-1099.
38. Capila I., Linhardt R.J. Heparin - Protein interactions. Angew Chem-Int Edit 2002, 41:391-412.
39. Nugent M.A., Edelman E.R. Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperactivity. Biochemistry 1992, 31:8876-8883.
40. Shu X.Z., Liu Y.C., Palumbo F.S., Lu Y., Prestwich G.D. In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 2004, 25:1339-1348.
41. Ghosh K., Shu X.Z., Mou R., Lombardi J., Prestwich G.D., Rafailovich M.H., et al. Rheological characterization of in situ cross-linkable hyaluronan hydrogels. Biomacromolecules 2005, 6:2857-2865.
42. Levental I., Georges P.C., Janmey P.A. Soft biological materials and their impact on cell function. Soft Matter 2007, 3:299-306.
43. Kim J., Kim I.S., Cho T.H., Lee K.B., Hwang S.J., Tae G., et al. Bone regeneration using hyaluronic acid-based hydrogel with bone morphogenic protein-2 and human mesenchymal stem cells. Biomaterials 2007, 28:1830-1837.
44. Liu Y., Shu X.Z., Prestwich G.D. Tumor engineering: orthotopic cancer models in mice using cell-loaded, injectable, cross-linked hyaluronan-derived hydrogels. Tissue Eng 2007, 13:1091-1101.
45. Schoenmakers R.G., van de Wetering P., Elbert D.L., Hubbell J.A. The effect of the linker on the hydrolysis rate of drug-linked ester bonds. J Control Release 2004, 95:291-300.
46. Bessa P.C., Casal M., Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2008, 2:81-96.
47. Shields L.B.E., Raque G.H., Glassman S.D., Campbell M., Vitaz T., Harpring J., et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006, 31:542-547.
48. Winn S.R., Uludag H., Hollinger J.O. Sustained release emphasizing recombinant human bone morphogenetic protein-2. Adv Drug Deliv Rev 1998, 31:303-318.
49. Goishi K., Higashiyama S., Klagsbrun M., Nakano N., Umata T., Ishikawa M., et al. Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell 1995, 6:967-980.
50. Bert J.L., Pearce R.H., Mathieson J.M., Warner S.J. Characterization of collagenous meshworks by volume exclusion of dextrans. Biochem J 1980, 191:761-768.
51. Higashiyama S., Lau K., Besner G.E., Abraham J.A., Klagsbrun M. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem 1992, 267:6205-6212.
52. Dorai T., Dutcher J.P., Dempster D.W., Wiernik P.H. Therapeutic potential of curcumin in prostate cancer - IV: interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate 2004, 60:1-17.
53. Foster B.A., Gingrich J.R., Kwon E.D., Madias C., Greenberg N.M. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997, 57:3325-3330.
54. Wang L.S., Chung J.E., Chan P.P.Y., Kurisawa M. Injectable biodegradable hydrogels with tunable mechanical properties for the stimulation of neurogenesic differentiation of human mesenchymal stem cells in 3D culture. Biomaterials 2010, 31:1148-1157.
55. Sugahara K.N., Hirata T., Hayasaka H., Stern R., Murai T., Miyasaka M. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem 2006, 281:5861-5868.
56. Ripple M., Mulcahy R.T., Wilding G. Characteristics of the glutathione/glutathione-S-transferase detoxification system in melphalan resistant human prostate cancer cells. J Urol 1993, 150:209-214.
57. Bailey H.H., Gipp J.J., Ripple M., Wilding G., Mulcahy R.T. Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res 1992, 52:5115-5118.
58. Helmlinger G., Netti P.A., Lichtenbeld H.C., Melder R.J., Jain R.K. Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol 1997, 15:778-783.
59. Butcher D.T., Alliston T., Weaver V.M. A tense situation: forcing tumour progression. Nat Rev Cancer 2009, 9:108-122.
60. Cheng G., Tse J., Jain R.K., Munn L.L. Micro-Environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells. PLoS ONE 2009, 4.
61. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61.
62. Kisker O., Onizuka S., Banyard J., Komiyama T., Becker C.M., Achilles E.G., et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 2001, 61:7298-7304.
63. Sokoloff M.H., Chung L.W.K. Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. Cancer Metastasis Rev 1998, 17:307-315.
64. Marjon P.L., Bobrovnikova-Marjon E.V., Abcouwer S.F. Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress. Mol Cancer 2004, 3:4.
65. Bao B.-Y., Yao J., Lee Y.-F. 1 alpha, 25-dihydroxyvitamin D-3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006, 27:1883-1893.
66. McGovern T., Risse P.-A., Tsuchiya K., Hassan M., Frigola G., Martin J.G. LTD(4) induces HB-EGF-dependent CXCL8 release through EGFR activation in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2010, 299:L808-L815.
67. Yagi H., Yotsumoto F., Miyamoto S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther 2008, 7:3441-3451.
68. Fujiyama S., Matsubara H., Nozawa Y., Maruyama K., Mori Y., Tsutsumi Y., et al. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001, 88:22-29.
69. Zhang Y., Wang L., Zhang M., Jin M., Bai C., Wang X. Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway. J Cell Physiol 2011, 227:35-43.
70. West D.C., Hampson I.N., Arnold F., Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985, 228:1324-1326.
71. Crawford H.C., Matrisian L.M. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1994, 14:234-245.